Abiraterone: Finance
Commons · Question 83371 · Tabled 20 Oct 2025 · Department of Health and Social Care · Official record
Answered 30 Oct 2025
Question
Asked by Louie French
To ask the Secretary of State for Health and Social Care, when the Clinical Priorities Advisory Group next plans to consider funding for Abiraterone in a prioritsation round.
Answer
Answered by Zubir Ahmed, 30 Oct 2025
NHS England considered abiraterone as an off-label treatment for hormone sensitive, non-metastatic prostate cancer through its clinical policy development process in 2024/25. Through this process, NHS England confirmed that there was sufficient supporting...